[Prevalence of hypercoagulation conditions in patients with thrombosis in Northern Navarra].
BACKGROUND
To determine the prevalence of hypercoagulability states in patients with thromboembolic disease in Septentrional Navarra.


METHODS
74 patients were studied (13 female, mean age [+/- SD] 43.5 +/- 13.9 years, range 22-81) with: deep venous thrombosis (DVT) with or without pulmonary embolism (PE) in 15 patients; ischemic stroke (IS) in 20 patients and; myocardial infarction (MI) in 39 patients. Antithrombin III, C protein (CP), plasminogen, plasminogen activator inhibitor (PAI), total S protein (TSP), free S protein (FSP), lupus anticoagulant (LA) and anticardiolipin antibodies (ACA) type IgG were determined in all patients.


RESULTS
The prevalence of hypercoagulability state was 27% in patients with thromboembolic disease; 26.6% in patients with PE (20% with ACA and 6.6% with CP deficiency); 30% in patients with IS (15% with ACA, CP deficiency in 5%, FSP deficiency in 5%, and PAI raising in 10%) and in the 25.6% of patients with MI (15.3% with ACA, 2.5% with CP deficiency, 2.5% with TSP and FSP deficiency and PAI raising in the 7.6%).


CONCLUSIONS
In Septentrional Navarra population with thromboembolic disease the presence of hypercoagulable states is high. In our study, the most common hypercoagulable state was the presence of ACA, followed by PAI raising and by the CP deficiency.
Benedicto Aguirre
E
E
Departamento de Medicina Interna, Clínica Universitaria de Navarra, Pamplona.
Yuste
J R
JR
Páramo
J A
JA
Rocha
E
E
Prieto
J
J
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D017152:Antibodies, Antiphospholipid / Q000097:blood; D001778:Blood Coagulation Disorders / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D013030:Spain / Q000453:epidemiology; D013923:Thromboembolism / Q000097:blood / Q000150:complications*
D017152:Antibodies, Antiphospholipid
Prevalencia de los estados de hipercoagulabilidad en pacientes con trombosis en Navarra Septentrional.